Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 75.00
Bid: 70.00
Ask: 80.00
Change: -2.50 (-3.23%)
Spread: 10.00 (14.286%)
Open: 77.50
High: 77.50
Low: 75.00
Prev. Close: 77.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

27 Jun 2016 07:00

RNS Number : 2776C
Biome Technologies PLC
27 June 2016
 

27 June 2016

 

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the six month period ending 30 June 2016. This update is being made ahead of the period end and in place of the trading update scheduled for the end of July. The interim results are expected to be announced on 31 August 2016.

 

Trading Update

Total Group revenues for the first half are expected to be £2.2m (H1 2015 £2.1m). Whilst this revenue is marginally ahead of last year's performance, it is below that of the Board's expectations. This shortfall is due to a reduced demand for already commercialised products in the Bioplastics Division and some slippage of the Stanelco RF's division's order pipeline into the second half.

 

The Group's cash position at 27 June 2016 is £1.0m (31 March 2016: £1.6m) reflecting the current trading activity and timing of anticipated cash receipts from work in progress in the Stanelco RF division.

 

Bioplastics Division

Revenues generated by the Bioplastics Division in the first half of 2016 totalled £0.6m (H1 2015 £1.0m).

It was noted in the trading update of 25 April 2016 that revenues in the Bioplastics division in the first quarter of 2016 were £0.2m (Q1 2015: £0.5m) reflecting the timings of campaign production runs of packaging and lidding materials for the US single-serve coffee market (coffee pods). Whilst revenues recovered in Q2 2016 to £0.4m with some additional campaigns, it had been expected by the Board that this recovery would be stronger.

 

Biome has been developing a suite of related materials to enable coffee pod producers to sell biodegradable end products to the US consumer market. This is an important advance for the market and has received supportive media comment. The materials Biome has been developing comprise the outer packaging and the lid, ring and "non-woven" filter of the pod. Each part has entailed significant development cost both in time and in production testing and we have worked in a collaborative way with the manufacturers of the pods and packaging in the US to achieve success. The packaging and lid materials have completed their development stages and have been in full production from the middle of last year. The ring and filter materials are in the advanced stages of development and we expect to move into commercialisation by the end of this year with these materials. Whilst the second half of this year should be favourably impacted as the ring reaches its commercialisation phase, it has now become clear that the inflexion point of significant revenue generation will be later in the half year than the Board has previously expected as Biome's customers complete their own work to industrialise this innovative product.

 

Throughout this broad programme, Biome has been continually re-assessing the likely demand for the portfolio of the Bioplastics division's materials, although this is made difficult by fluctuating underlying market growth, the rise in demand for such bio-degradable products as they become available and, contrarily, improving efficiencies in our customers' production processes. The Group has just completed such a review and the Board continues to believe that the long-term outlook for these products remains very positive. In the short term, however, it believes the likely demand will be less than originally thought. This will result in a near-term fall in anticipated revenues. A similar review will be undertaken at the end of August, prior to the Group's Interim Statement.

 

Stanelco RF Technologies Division

Revenues for this division in the first half of 2016 were £1.6m (2015: £1.3m), slightly behind the Board's expectations. Whilst a number of the prospective orders for the second half are still being finalised, the division has a healthy enquiry book forward into 2017.

 

Group Outlook

Group revenues at the mid-year point are behind the Board's expectations. Whilst margins have been robust and the operating loss for the period is anticipated to be lower than for the same period in 2015, it will be behind the Board's expectations.

 

Whilst the Board is confident that revenue growth should accelerate in the second half of the year, it is now likely that the Group's full year performance will be significantly behind current market expectations, with the Board now expecting Group revenues for the year to 31 December 2016 to be only marginally ahead of those achieved in the prior year.

 

 

- Ends -

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Richard Short (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAKADNFBKDFAB
Date   Source Headline
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.